Martine Rothblatt, an insider at United Therapeutics Corp (UTHR), sold 130 shares of the company's stock on December 4, 2025, at a price of $484.31 per share. This transaction totaled approximately $63,000. Following this sale, Rothblatt retains 130 shares in the company.
United Therapeutics, a biotechnology firm headquartered in Silver Spring, Maryland, specializes in developing and commercializing therapies for patients with chronic and life-threatening conditions. The company employs 1,305 individuals and markets several products aimed at treating pulmonary arterial hypertension (PAH), including Tyvaso DPI and Remodulin. United Therapeutics also offers oncology treatments such as Unituxin for high-risk neuroblastoma.
With a market capitalization of $20.5 billion, the company has a trailing P/E ratio of 16.16 and an EPS of 26.41. Investors should note that insider transactions must be reported to the SEC, providing transparency regarding the actions of company executives. While Rothblatt's sale may raise questions, such transactions can occur for various reasons, including personal financial needs or estate planning.
Upcoming earnings reports are scheduled for April 28, 2026, with an estimated EPS of $7.37 and revenue of $834.2 million, and July 28, 2026, with an estimated EPS of $7.57 and revenue of $864.0 million. Investors are encouraged to consider a broader context of insider activity rather than focusing solely on individual transactions.